
Jarushka Naidoo/X
Dec 25, 2024, 02:57
Jarushka Naidoo: Important paper on incidence and outcomes of EGFR+ NSCLC
Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin (Ireland), posted the following on X:
“Important paper on incidence and outcomes of molecular subtypes of EGFR+ NSCLC in JTO and JTO CRR.
– 5,212 patients with EGFR+ NSCLC.
– 8.9% had uncommon EGFR mutations.
– Median time on TKIs 4.1m vs 10.9m (common) and 12.4m (compound).
Congratulations Alfredo Addeo et al.”
Authors: Daniele Tavernari, Maxime Borgeaud, Ximeng Liu, Parikh Kaushal, Xiuning Le, Giovanni Ciriello, Alfredo Addeo
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 3, 2025, 15:56
Mar 3, 2025, 15:51
Mar 3, 2025, 15:49
Mar 3, 2025, 15:48